Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · IEX Real-Time Price · USD
20.78
-0.37 (-1.75%)
At close: Jul 19, 2024, 4:00 PM
20.31
-0.47 (-2.26%)
Pre-market: Jul 22, 2024, 7:00 AM EDT

Nurix Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Dec - Nov.
Year Ending
CurrentNov 30, 2023Nov 30, 2022Nov 30, 2021Nov 30, 2020
Market Capitalization
1,3383025841,2861,656
Market Cap Growth
61.23%-48.35%-54.57%-22.36%-
Enterprise Value
923432861,0031,375
PE Ratio
--2.10-3.24-10.97-38.30
PS Ratio
21.483.9215.1243.2292.93
PB Ratio
3.611.511.923.765.71
P/FCF Ratio
-7.31-3.36-3.40-14.28-357.44
P/OCF Ratio
-8.06-3.71-3.66-15.24-20700.24
EV/Sales Ratio
14.820.577.4133.7177.14
EV/EBITDA Ratio
-2.40-0.33-1.69-9.04-22.32
EV/EBIT Ratio
-2.18-0.30-1.59-8.57-21.55
EV/FCF Ratio
-3.39-0.48-1.66-11.14-296.72
Debt / Equity Ratio
0.080.150.040.04-
Debt / EBITDA Ratio
-0.19-0.23-0.07-0.12-
Debt / FCF Ratio
-0.27-0.34-0.07-0.14-
Quick Ratio
5.503.324.394.566.32
Current Ratio
5.573.404.514.706.70
Asset Turnover
0.170.220.090.060.08
Return on Equity (ROE)
-67.80%-59.50%-59.20%-33.80%-37.20%
Return on Assets (ROA)
-44.40%-41.60%-42.20%-24.90%-19.60%
Return on Capital (ROIC)
-44.83%-67.10%-58.25%-33.18%-22.39%
Earnings Yield
-12.33%-47.71%-30.88%-9.11%-2.61%
FCF Yield
-7.92%-29.75%-29.45%-7.00%-0.28%
Buyback Yield / Dilution
-14.96%-11.79%-13.32%-173.68%-376.03%
Total Shareholder Return
-14.96%-11.79%-13.32%-173.68%-376.03%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).